Merkel cell carcinoma responds to first-line pembrolizumab
The objective response rate wad 56% among 25 patients...
Source: Skin and Allergy News - Category: Dermatology Source Type: news
More News: Allergy | Allergy & Immunology | Cancer | Cancer & Oncology | Carcinoma | Dermatology | Merkel Cell Carcinoma | Skin | Study